While SCLC is known for its high mutational load [3] and devastating prognosis, NSCLC includes targetable oncogenic driver mutations [4], such as Kirsten rat sarcoma (KRAS) [5], epidermal growth factor receptor (EGFR) [6,7], anaplastic lymphoma kinase (ALK) [8], Serine/threonine-protein kinase B-rapidly accelerated fibrosarcoma (BRAF) [9,10], rearranged during transfection (RET) [11], Proto-oncogene tyrosine-protein kinase ROS (ROS1) [12] and rarely neurotrophic tropomyosin receptor kinases (NTRK) [13]. Here, ROS1 is linked to non-small cell lung carcinoma.